Three hospitalized non-critical COVID-19 subphenotypes and change in intubation or death over time: A latent class analysis with external and longitudinal validation
William S Stringer,
Amy S Labar,
Joshua D Geleris,
Evan V Sholle,
David A Berlin,
Claire M McGroder,
Matthew J Cummings,
Max R O’Donnell,
Haoyang Yi,
Xuehan Yang,
Ying Wei,
Edward J Schenck and
Matthew R Baldwin
PLOS ONE, 2025, vol. 20, issue 3, 1-15
Abstract:
Background: There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown. Objective: To identify and validate non-critical COVID-19 subphenotypes at hospital admission that may elucidate pathobiology and facilitate heterogeneity-of-treatment effect analyses of clinical trials with non-critical COVID-19 patients. Methods: We conducted a multi-center retrospective cohort study of adults hospitalized with COVID-19 who were not intubated or did not die within 24 hours of admission. We derived and externally and longitudinally validated subphenotypes during the wild-type and delta severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV2) waves via latent class analysis using clinical and laboratory data at hospital admission. We trained XGBoost machine learning models to predict subphenotype. Results: We analyzed data for 4,827 hospitalized non-critical COVID-19 patients: 2,077 wild-type wave Columbia University Medical Center (CUMC) and affiliate hospital derivation cohort patients; 1,214 wild-type wave Cornell Medical Center and affiliate hospital external validation cohort patients; and 1,536 delta wave CUMC and affiliate hospital longitudinal validation cohort patients. A three-class latent class model best fit each cohort identifying subphenotypes that were low-inflammatory, intermediate-inflammatory, and high-inflammatory with fibrinolysis, with increasing 90-day risk of intubation or death across subphenotypes in the wild-type wave. However, in the delta wave, the intermediate-inflammatory subphenotype had the lowest 90-day risk of intubation or death. XGBoost model area under the receiver-operating-curve was 0.96 in the testing dataset, and biomarkers of inflammation and cardiorenal dysfunction were the strongest predictors of subphenotype. Conclusion: We identified three hospitalized non-critical COVID-19 subphenotypes that persisted through the wild-type and delta SARS-CoV2 waves. The intermediate-inflammatory subphenotype had the greatest relative improvement in intubation and survival over time with the standardized use of corticosteroids and other interventions. Our machine learning model can facilitate heterogeneity-of-treatment effect analyses of clinical trials of adults hospitalized with non-critical COVID-19.
Date: 2025
References: Add references at CitEc
Citations:
Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0316434 (text/html)
https://journals.plos.org/plosone/article?id=10.13 ... 16434&type=printable (application/pdf)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0316434
DOI: 10.1371/journal.pone.0316434
Access Statistics for this article
More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().